Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Nothing less will reassure the public
The British medical research community is busy
assembling its response to research misconduct. The question is no
longer, "Do we have a problem?" but rather, "How can we best
respond?" The BMJ has thus commissioned five answers
to the question (p 1726),1 two from people outside Britain
with extensive experience of research misconduct. One recurrent theme
is that Britain needs a central body to lead on this difficult issue.
The answers are published in a week when we have to retract yet
another article because of probable fraud (p 1700).2 One
of the authors of the retracted paper was recently struck off by the
General Medical Council for research misconduct.
3 4
He
had also lied about his qualifications. Cameron Bowie, his coauthor,
then started from the inevitable assumption that all of the rest of his
work was fraudulent until proved otherwise and found that he could not
satisfy himself that his coauthor had completed the work he said he
had. Bowie describes his miserable experience in a personal view and
has retracted a paper that has gained wide attention and been
influential in developing policy (p 1755).5
This week also sees the publication of the first annual report from the
Committee on Publication Ethics (COPE),6 a body set up by
medical editors to support each other in tackling suspected research
misconduct and considering the ethical problems that arise all the time
in scientific publishing.7-9 The group has considered 25 cases, many of them minor, but in the past year In the introduction to the annual report Mike Farthing, the
chairman of COPE, argues that Britain needs a national agency to manage
research misconduct.10 The same message comes from Povl
Riis, one of the founders of the Danish committee,1 and
from Drummond Rennie, deputy editor (west) of JAMA and a
member of the United States Commission on Research
Integrity.1 Rennie pleads with Britons to learn from the
United States' experience, which goes back 20 years. In the early days
in the US each institution created its own rules for dealing with
research misconduct. "The results," writes Rennie, "were
frequently slow, bungled, idiosyncratic, and unfair to almost
everybody." So was born the Office of Research Integrity to oversee
and enforce institutions' compliance with federal regulations
governing research.
Another important message from the US is that a legal rather than a
scientific method is needed for managing cases of misconduct.
"Scientists," writes Rennie, "are not trained in conflict
resolution; their intuitive response is usually wrong and they tend to
set up shaky ad hoc procedures that do not guarantee the accused notice
of all the charges, the opportunity to respond to all the charges, and
a decision based on rigorous standards."1 COPE has been
lucky to receive the help of Ian Kennedy, a professor of law.
The president of the GMC, Sir Donald Irvine, has set up a committee
chaired by George Alberti, president of the Royal College of
Physicians, to consider a better response to research misconduct. The
committee includes the secretary of the Medical Research Council, which
has now produced excellent advice on how allegations of misconduct
should be investigated in its own units.
1 11
Crucially,
it offers a procedure to follow in that very first and awkward stage
when misconduct is suspected but far from proved. This is the stage
that editors find so difficult: they have strong suspicions but no
more There is an understandable reluctance to create a national body to lead
on research misconduct. Nobody wants more quangos than are absolutely
necessary, and everybody would like to think that local
bodies The British public BMJ Acknowledgments
RS is a member of the GMC's committee that is
considering research misconduct.
as a result of COPE
I
personally have referred an author to the General Medical Council (to
discover that he had already been struck off) and made a complaint to a
chief executive of a trust. It's a terrible thing to refer an author
to such authorities, but editors have decided that we can no longer
ignore misconduct. Nor can we investigate and punish, which is why we
must refer authors to their employers or other authorities. Our
experience with COPE makes it clear that once editors begin to pay
serious attention to misconduct it is there before their eyes.
and no means to investigate. One problem with the emerging
British response is that it doesn't cover all scientific research, but
the National Academies Policy Advisory Group (a group that covers the
bodies representing scientists, engineers, doctors, and the humanities)
has also been studying research misconduct. It unfortunately is still
at the stage of deciding whether there is a problem.
universities or research institutions
can keep their own
houses in order. Unfortunately the experience from the United States
and from other countries that have acted on research misconduct and
from Britain so far is that local responses are often inadequate. The
institutions don't have enough experience and face a terrible conflict
of interest in exposing one of their staff as a fraudster. A national
body should take the lead in defining research misconduct, developing
procedures for dealing with accusations, and ensuring that institutions
comply with them. In addition
and ultimately more importantly
the
national body could also lead in studying and preventing the problem.
stunned by the revelations from the Bristol case of
surgeons continuing to operate when they knew their results were poor
(p 1685)12
needs reassurance that everything possible is
being done to ensure the purity of the research record. A national body
is needed to provide that reassurance.
© BMJ 1998
the MRC's approach An editor's response to fraudsters Deception: difficulties and initiatives Honest advice from Denmark
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+